1. Medicines
  2. Cardiology
  3. LEQVIO® (Inclisiran)
  4. How Leqvio® works

Click here for Prescribing Information

How Leqvio® works

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

Leqvio® works differently from other LDL-C-lowering therapies by harnessing the intrinsic process of RNAi to increase hepatic LDL-C uptake and reduce LDL-C levels in the bloodstream.1-3 

Watch the video below to learn more about the mechanism of action of Leqvio®.

 

Multiple factors explain the sustained duration of effect of Leqvio®:

Chemical modifications increase the stability of Leqvio® by decreasing its susceptibility to degradation from exonucleases and endonucleases4
Leqvio® is slowly released from the hepatic endosomes into the cytoplasm4
   
Formation of the LEQVIO®-RISC complex protects Leqvio® and enhances its duration of action4   
A single siRNA(Leqvio®)-bound RISC complex can cleave many target protein-coding mRNA transcripts5
 

 

injection icon

Learn more about the Leqvio® clinical trial data

Click here
 

 

Leqvio® is not reimbursed in Ireland at this time.

 

LDL-C, low-density lipoprotein cholesterol; mRNA, messenger ribonucleic acid; RISC, RNA-induced silencing complex; RNAi, ribonucleic acid interference; siRNA, small interfering ribonucleic acid.

References

  1. Leqvio® Summary of Product Characteristics. Accessed August 2022 at www.ema.europe.eu

  2. Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442.

  3. Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.

  4. Khvorova A. N Engl J Med 2017;376(1):4–7. 

  5. Fitzgerald K et al. N Engl J Med 2017;376(1):41–51.

Rate this content: 
No votes yet
March 2023 | IE189349
Print
×

Ask Speakers

×

Medical Information Request

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.